Search results
Results From The WOW.Com Content Network
In the management of Parkinson's disease, due to the chronic nature of Parkinson's disease (PD), a broad-based program is needed that includes patient and family education, support-group services, general wellness maintenance, exercise, and nutrition. At present, no cure for the disease is known, but medications or surgery can provide relief ...
The history of Parkinson's disease expands from 1817, when British apothecary James Parkinson published An Essay on the Shaking Palsy, to modern times. Before Parkinson's descriptions, others had already described features of the disease that would bear his name , while the 20th century greatly improved knowledge of the disease and its ...
Parkinsonism is a clinical syndrome characterized by the four motor symptoms found in Parkinson's disease: tremor, bradykinesia (slowed movements), rigidity, and postural instability. [1] [2] Parkinsonism gait problems can lead to falls and serious physical injuries. Other common symptoms include:
Parkinson's typically manifests in individuals over 60, with about one percent affected. In those younger than 50, it is termed "early-onset PD". No cure for Parkinson's is known, and treatment focuses on alleviating symptoms. Initial treatment typically includes L-DOPA, MAO-B inhibitors, or dopamine agonists.
Chapter 427: Parkinson's Disease; Chapter 428: Tremor, Chorea, and Other Movement Disorders; Chapter 430: Prion Diseases; Chapter 431: Ataxic Disorders; Chapter 432: Disorders of the Autonomic Nervous System; Chapter 433: Trigeminal Neuralgia, Bell's Palsy, and Other Cranial Nerve Disorders; Chapter 434: Diseases of the Spinal Cord
In the same year, the Parkinson's Foundation and Merck, Inc. funded Dr. Yahr's double-blind clinical trial of carbidopa/levodopa (Sinemet), which remains the gold standard therapy for Parkinson's disease. [10] In the 1980s, the Parkinson's Foundation began investing in movement disorder training fellowships at Columbia University and Rush ...
Parkinson-plus syndromes are usually more rapidly progressive and less likely to respond to antiparkinsonian medication than PD. [10] [11] However, the additional features of the diseases may respond to medications not used in PD. [citation needed] Current therapy for Parkinson-plus syndromes is centered around a multidisciplinary treatment of ...
Glomus cells are derived from the neural crest and secrete dopamine in response to hypoxemia (low level of oxygen in the blood). [10] Based on their ability to secrete dopamine and also glial cell-derived neurotrophic factor (GDNF), [11] these cells have been investigated as an intrastriatal autograft therapy for patients with Parkinson's disease.